STOCK TITAN

Lumos Pharma Inc - LUMO STOCK NEWS

Welcome to our dedicated news page for Lumos Pharma (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lumos Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lumos Pharma's position in the market.

Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) announces abstracts accepted for presentation at upcoming medical meetings regarding its Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD). Data shows oral therapeutic candidate LUM-201 produces comparable growth to injectable rhGH with less exposure to circulating GH, potentially revolutionizing treatment for growth hormone disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
-
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) receives a Notice of Allowance from the USPTO for a novel formulation patent for LUM-201, extending intellectual property protection through 2042. The patent covers improved formulations to be used in Phase 3 trials and commercialization, offering potential benefits for pediatric patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
none
-
Rhea-AI Summary
Lumos Pharma, Inc. announces successful Phase 2 trials for LUM-201 in moderate PGHD, with positive topline data and upcoming Phase 3 trial initiation. The company reported financial results for 2023, showing a cash position of $36.1 million. Dr. Duke appointed as Chief Medical Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) to announce full year 2023 financial results after market close on March 7, 2024. The company will host a conference call to discuss financial results, clinical progress, and corporate activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences earnings
-
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14, 2024. The company's management will present and host virtual one-on-one meetings with the investment community. The webcast will be available on the company's website, and a replay of the presentation will be accessible for 90 days. Contact Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.9%
Tags
conferences
-
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) promotes Dr. Duke to Chief Medical Officer, focusing on clinical and regulatory strategy for Phase 3 trial of oral LUM-201 in treating pediatric growth hormone deficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
Rhea-AI Summary
Lumos Pharma, Inc. (LUMO) to Host Webinar on December 6, 2023 to Discuss Phase 2 OraGrowtH210 and OraGrowtH212 Trials Results with Esteemed Thought Leaders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences clinical trial
-
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) will participate in the Piper Sandler 35th Annual Healthcare Conference in New York City from November 28th – 30th. The company's management will present and host one-on-one meetings. A fireside chat is scheduled for November 30th at 2:30 PM EST, with a webcast available on the company's website. The presentation replay will be accessible for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) announced positive Phase 2 trial results for its oral therapeutic LUM-201 for moderate pediatric growth hormone deficiency (PGHD), with the optimal dose identified as 1.6 mg/kg/day. The trials met primary and secondary endpoints, achieving AHVs of 8.2 cm/yr at 6 months and 8.0 cm/yr at 12 months. Cash position at the end of Q3 2023 was $42.7 million, supporting operations through Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
Rhea-AI Summary
Lumos Pharma, Inc. (NASDAQ:LUMO) announced that Phase 2 data from its OraGrowtH210 and OraGrowtH212 trials demonstrate that LUM-201 achieved annualized height velocities (AHV) of 8.2 cm/yr at 6 months and 8.0 cm/yr at 12 months, comparable to growth rates for moderate PGHD population. The data also validated the predictive enrichment marker (PEM) strategy and demonstrated the unique pulsatile mechanism of LUM-201.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.71%
Tags
Lumos Pharma Inc

Nasdaq:LUMO

LUMO Rankings

LUMO Stock Data

21.40M
5.30M
34.68%
29.34%
3.55%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Austin

About LUMO

lumos pharma is an clinical stage biotechnology company focused on developing therapeutics for rare diseases